DBV Technologies announced a $50 million capital raise through the issuance of new American Depositary Shares (ADS) under its At-The-Market (ATM) program on Nasdaq. The placement involves issuing 3.66 million ADS, each representing five ordinary shares, at a price of $13.67 per ADS. This funding will support DBV's advanced-stage biopharmaceutical work, particularly its VIASKIN® platform for treating food allergies using immunotherapy. The new shares will dilute existing shareholders by about 5.82%, with the issuance expected to complete by August 3, 2026. This capital raise strengthens DBV's financial position to continue clinical trials and development of allergy treatments.
Real REMAX Group finalized its acquisition of RE/MAX Holdings on August 24, 2026, forming a combined company with over 180,000 agents worldwide. The new entity trades on Nasdaq under the ticker REAX and blends Real's technology platform with RE/MAX's...
Build-A-Bear Workshop reported Q2 earnings per share of $0.70, beating analyst estimates despite a decline from $0.94 last year. However, revenue fell 7.2% year-over-year to $115.29 million, missing expectations and leading to a lowered annual sales ...
Affirm Holdings, a leader in buy now, pay later services, is set to report strong Q2 earnings with an expected EPS of $0.35 and revenue of $1.11 billion, up 26.2% year-over-year. Growth is driven by a 29.3% increase in Gross Merchandise Volume and a ...
Amphenol Corporation plans a 2-for-1 stock split on September 3, 2026, doubling shares while keeping investment value steady. The company shows strong growth, especially in its Communications Solutions segment, driven by AI-related IT demand and acqu...
Toronto-Dominion Bank reported a strong Q3 with earnings per share of $1.97 and revenues of $12.07 billion, both exceeding analyst expectations. This performance was driven by robust growth in its capital markets and Canadian banking divisions, along...
